Dudediligence.

Anixa Biosciences, Inc

ANIXNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Net income, by quarter
−$2.9MOct ’24−$3.2MJan ’25−$2.8MApr ’25−$2.3MJul ’25−$2.7MOct ’25−$2.6MJan ’26−$2.5MApr ’26−$2.6MJul ’26
Fiscal years, by the month each ended
LineOct 2021Oct 2022Oct 2023Oct 2024Oct 2025
Revenue$512,000none on file$210,000none on filenone on file
Operating income−$13.1M−$13.9M−$11.0M−$13.8M−$11.7M
Net income−$13.0M−$13.6M−$9.8M−$12.6M−$10.9M
Operating cash flow−$4.9M−$6.5M−$6.2M−$7.3M−$7.2M
Cash$29.1M$12.4M$915,000$1.3M$1.2M
Shares outstanding30.1M30.9M31.1M32.2M33.0M